Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Harnett Sheehan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Psychopharmacology Bulletin|February 8, 2007
Current approaches to the pharmacologic treatment of anxiety disordersDavid V Sheehan, Kathy Harnett Sheehan
International Clinical Psychopharmacology|February 28, 2008
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleKathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|May 22, 2007
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B A Raj
Innovations in Clinical Neuroscience|December 19, 2014
Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical ReviewDavid V Sheehan, Jennifer M Giddens, Kathy Harnett Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?Jennifer M Giddens, Kathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|March 26, 2008
Efficacy of print advertising for a bipolar disorder studySumeet Roy, Shilpa Patel, Kathy Harnett Sheehan, et al.
Psychopharmacology Bulletin|November 17, 2007
An open-label study of tiagabine in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B Ashok Raj, et al.
International Clinical Psychopharmacology|November 25, 2010
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scaleDavid V Sheehan, Kathy Harnett-Sheehan, Melissa E Spann, et al.
Journal of Affective Disorders|August 28, 2012
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patientDavid V Sheehan, Kathy Harnett-Sheehan, Rosario B Hidalgo, et al.
Assessment|September 25, 2003
The Tourette's Disorder Scale (TODS): development, reliability, and validityR Douglas Shytle, Archie A Silver, Kathy Harnett Sheehan, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Psychopharmacology Bulletin|February 8, 2007
Current approaches to the pharmacologic treatment of anxiety disordersDavid V Sheehan, Kathy Harnett Sheehan
International Clinical Psychopharmacology|February 28, 2008
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleKathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|May 22, 2007
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B A Raj
Innovations in Clinical Neuroscience|December 19, 2014
Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical ReviewDavid V Sheehan, Jennifer M Giddens, Kathy Harnett Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?Jennifer M Giddens, Kathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|March 26, 2008
Efficacy of print advertising for a bipolar disorder studySumeet Roy, Shilpa Patel, Kathy Harnett Sheehan, et al.
Psychopharmacology Bulletin|November 17, 2007
An open-label study of tiagabine in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B Ashok Raj, et al.
International Clinical Psychopharmacology|November 25, 2010
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scaleDavid V Sheehan, Kathy Harnett-Sheehan, Melissa E Spann, et al.
Journal of Affective Disorders|August 28, 2012
Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patientDavid V Sheehan, Kathy Harnett-Sheehan, Rosario B Hidalgo, et al.
Assessment|September 25, 2003
The Tourette's Disorder Scale (TODS): development, reliability, and validityR Douglas Shytle, Archie A Silver, Kathy Harnett Sheehan, et al.
Pageof 2